ReviewJournal of personalized medicine2022
MicroRNAs-A Promising Tool for Asthma Diagnosis and Severity Assessment: A Systematic Review.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- MicroRNA-mediated regulation of inflammatory gene expression in asthma.Inflammopharmacology · 2026Review
- MicroRNAs as Diagnostic and Therapeutic Biomarkers in Childhood Asthma: A Systematic Review with Bioinformatics Analysis.Journal of personalized medicine · 2026Review
- MicroRNAs in Asthma: A Replication-Based Review of Human Evidence.Journal of inflammation research · 2026Review
- Creation of a Novel Coding Program to Identify Genes Controlled by miRNAs During Human Rhinovirus Infection.Methods and protocols · 2025Article
- Circulating microRNAs as Potential Diagnostic Tools for Asthma and for Indicating Severe Asthma Risk.International journal of molecular sciences · 2025Article
- Urinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers.Biomolecules · 2025Article
- Specific microRNA Profile Associated with Inflammation and Lipid Metabolism for Stratifying Allergic Asthma Severity.International journal of molecular sciences · 2024Article
- Lung proinflammatory microRNA and cytokine expression in a mouse model of allergic inflammation: role of sex chromosome complement and gonadal hormones.Physiological genomics · 2024Article
- The Roles of MicroRNAs in Asthma and Emerging Insights into the Effects of Vitamin DNutrients · 2024Review
- Obese Asthma Phenotype Is Associated with hsa-miR-26a-1-3p and hsa-miR-376a-3p Modulating the IGF Axis.International journal of molecular sciences · 2023Article
- Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles.International journal of molecular sciences · 2023Review
- Circulating MicroRNAs Expression Profile in Lung Inflammation: A Preliminary Study.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Micro RNAs (miRNAs) are short, non-coding RNAs (Ribonucleic acids) with regulatory functions that could prove useful as biomarkers for asthma diagnosis and asthma severity-risk stratification. The objective of this systematic review is to identify panels of miRNAs that can be used to support asthma diagnosis and severity-risk assessment. Three databases (Medline, Embase, and SCOPUS) were searched up to 15 September 2020 to identify studies reporting differential expression of specific miRNAs in the tissues of adults and children with asthma. Studies reporting miRNAs associations in animal models that were also studied in humans were included in this review. We identified 75 studies that met our search criteria. Of these, 66 studies reported more than 200 miRNAs that are differentially expressed in asthma patients when compared to non-asthmatic controls. In addition, 16 studies reported 17 miRNAs that are differentially expressed with differences in asthma severity. We were able to construct two panels of miRNAs that are expressed in blood and can serve as core panels to further investigate the practicality and efficiency of using miRNAs as non-invasive biomarkers for asthma diagnosis and severity-risk assessment, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.